Novel Combination Therapy for Obesity Shows Promising Safety and Efficacy

Obesity is a complex chronic disease associated with numerous health complications, including type 2 diabetes, cardiovascular disease, and certain cancers. Current treatments, such as tirzepatide (a dual GIP and GLP-1 receptor agonist), have shown significant efficacy in weight management and glycemic control. However, there remains a need for even more effective and well-tolerated therapies. This Phase 1 study aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of a novel compound, LY3457263, when combined with tirzepatide in overweight or obese individuals.

The combination of LY3457263 and tirzepatide was generally well-tolerated, with most adverse events being mild to moderate gastrointestinal issues such as nausea (25% vs. 10% for tirzepatide alone) and diarrhea (18% vs. 8%). No serious adverse events were reported in any treatment group. Pharmacokinetic analysis revealed a dose-proportional increase in LY3457263 exposure, with a half-life supporting weekly dosing. The highest dose of LY3457263 in combination with tirzepatide resulted in a mean body weight reduction of 18.2% from baseline, significantly greater than the 12.5% reduction observed with tirzepatide alone (p<0.001). Furthermore, participants receiving the combination therapy showed a 2.5-fold greater improvement in fasting glucose levels compared to the tirzepatide monotherapy group (p<0.01), and a 43% reduction in HbA1c in those with prediabetes.